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Abbreviations:  
Apc:  Adenomatous polyposis coli gene 
CD45: Cluster of differentiation 45 antigen which is synonymous with leukocyte common antigen 
CD11b: Cluster of differentiation 11beta which is synonymous with integrin subunit alpha-M 
DCIS:  Ductal carcinoma in situ 
EIF4G:  Eukaryotic initiation factor 4 gamma 
EMT: epithelial to mesenchymal transition 
F4/80: antigen encoded by the Adgre1 locus used as a monocyte-macrophage marker in mice  
IDC: Invasive ductal carcinoma 
IRES:  Internal ribosome entry site 
KO:  Knock-out 
LOH:  Loss of heterozygosity 
MET:  mesenchymal to epithelial transition 
MMTV: Mouse mammary tumor virus 
P120:  the Delta catennin protein encoded by the CTNND1 gene   
PyMT: Polyoma Middle T antigen 
Rho:  Family of GTPases that belongs to the Ras superfamily of proteins, includes Rac1, Cdc42   and 
RhoA 
RNA: Ribonucleic acid 
ROCK1: Rho associated coiled-coil containing protein kinase 1 
RNA: Ribonucleic acid 
RT-qPCR: Real-time quantitative polymerase chain reaction 





































We have examined the effects of targeted p120 KO in a PyMT mouse model of invasive ductal 
(mammary) cancer (IDC).  Mosaic p120 ablation had little effect on primary tumor growth but caused 
significant pro-metastatic alterations in the tumor microenvironment leading ultimately to a marked 
increase in the number and size of pulmonary metastases. Surprisingly, although early effects of 
p120-ablation included decreased cell-cell adhesion and increased invasiveness, cells lacking p120 
were almost entirely unable to colonized distant metastatic sites in vivo.  The relevance of this 
observation to human IDC was established by analysis of a large clinical dataset of 1126 IDCs. As 
reported by others, p120 downregulation in primary IDC predicted worse overall survival. However, 
as in the mice, distant metastases were almost invariably p120 positive, even in matched cases 
where the primary tumors were p120 negative. Collectively, our results demonstrate a strong positive 
role for p120 (and presumably E-cadherin) during metastatic colonization of distant sites. On the 
other hand, downregulation of p120 in the primary tumor enhanced metastatic dissemination 
indirectly via pro-metastatic conditioning of the tumor microenvironment. 
 
 




































 Breast cancer is the second most common cause of cancer-related death in women. Although 
management of the disease has improved significantly over the last 10 years, metastasis remains a 
significant problem and the leading cause of mortality. Nonetheless, metastatic dissemination is a 
remarkably inefficient process(Valastyan and Weinberg 2011). To successfully colonize distant sites 
in the body, cells from the primary tumor must acquire de novo the ability to (i) invade locally, (ii) 
enter into circulation (intravasate), (iii) exit from circulation at a distant location (extravasate), and (iv) 
thereafter survive as micrometastatic colonies in an otherwise hostile environment.  Disseminated 
micrometastases are clinically undetectable and can remain dormant for years (Valastyan and 
Weinberg 2011, Brabletz 2012). The final and rate-limiting step in the metastatic cascade, termed 
colonization, occurs when micrometastatic lesions emerge from dormancy to form clinically relevant 
macrometastatic tumors.  
Though many factors underlying these events are not well understood (Kang and Pantel 2013) 
metastasis is frequently linked to genetic and/or epigenetic dysregulation of E-cadherin, the 
predominant cell-cell adhesion molecule in epithelial tissues and master organizer of the epithelial 
phenotype (Fan, Jin et al. 2019). As with other classical cadherins, its extracellular domains connect 
like cells via calcium-dependent homophilic interaction (Kim, Tai et al. 2011). Strong adhesion, 
however, is critically dependent on a group of cytoplasmic cadherin binding partners, namely α-, β- 
and p120-catenins, each of which also contributes indispensably to E-cadherin's role as a tumor 
suppressor (Jeanes, Gottardi et al. 2008, Schackmann, Tenhagen et al. 2013, Sun, Zhang et al. 
2014).  Notably, direct interaction of E-cadherin with p120 is required for E-cadherin stability and 
retention on the cell surface. In many cell types, cadherin adhesion is compromised or lost altogether 
upon removal of p120, as the remaining components of the complex are then internalized by 
endocytosis and degraded (Thoreson, Anastasiadis et al. 2000, Ozawa 2003, Wehrendt, Carmona 
et al. 2016).  
 Consistent with these observations, experiments in mice based on targeted p120 ablation in various 
epithelial tissues have revealed potentially causal links to cancer in the salivary gland  (Davis and 
Reynolds 2006) esophagus (Stairs, Bayne et al. 2011),  skin (Perez-Moreno, Song et al. 2008), 
pancreas (Hendley, Wang et al. 2016), intestine (Smalley-Freed, Efimov et al. 2011), and breast 
(Kurley, Bierie et al. 2012, Schackmann, Klarenbeek et al. 2013, El Sharouni, Postma et al. 2017). 
In vivo p120 KO phenotypes vary widely, however, depending on the organ (Perez-Moreno, Davis 
et al. 2006, Oas, Xiao et al. 2010, Smalley-Freed, Efimov et al. 2010), the degree of p120 depletion 
(Richert, Phadke et al. 2005)  and the context under which p120 depletion occurs (Mastracci, Tjan 
et al. 2005, Macpherson, Hooper et al. 2007, Short, Kondo et al. 2017).  During prostate maturation, 
for example, adhesion is largely unaffected by p120 KO despite near-complete loss of E-cadherin 


































disassembled, as epithelial adhesion is lost altogether (Kurley, Bierie et al. 2012).  Interestingly, 
tumorigenic effects of p120 ablation in the skin (Perez-Moreno, Song et al. 2008) and the esophagus 
(Stairs, Bayne et al. 2011) were linked not to defective adhesion but rather a cell-autonomous 
inflammatory response (Perez-Moreno, Davis et al. 2006, Smalley-Freed, Efimov et al. 2010, Stairs, 
Bayne et al. 2011, Hu 2012). By contrast, in Apc mouse models of intestinal cancer, tumorigenesis 
was effectively blocked upon loss of both p120 alleles due to synthetic lethal interaction with the loss 
of Apc (Short, Kondo et al. 2017). Loss of just one p120 allele, on the other hand, resulted in up to a 
10-fold increase in tumor multiplicity (Short, Kondo et al. 2017). In mouse models of pancreatic 
cancer, monoallelic p120 ablation was associated with metastasis to the liver  while loss of both p120 
alleles led to pulmonary metastases (Reichert, Bakir et al. 2018) revealing an unexpected dose-
dependent effect of p120 downregulation on metastatic organotropism.  
In breast cancer (BC), specific subtypes have been selectively linked to altered levels of p120 and/or 
E-cadherin. Inflammatory BC, for example, is associated with p120 upregulation by an EIF4G and 
IRES-mediated mechanism that leads to abnormally stable E-cadherin and the formation of highly 
metastatic tumor emboli (Silvera and Schneider 2009)(Silvera, Arju et al. 2009). In contrast, lobular 
BC is associated with complete loss of E-cadherin at a very early stage in its development (Berx, 
Cleton-Jansen et al. 1995) (Vos, Cleton-Jansen et al. 1997, Singhai, Patil et al. 2011), a phenotype 
largely recapitulated by E-cadherin ablation in p53 KO mice (Schackmann, Klarenbeek et al. 
2013)(Derksen, Braumuller et al. 2011).  With the loss of E-cadherin, p120 mis-localizes to the 
cytoplasm and metastases occur by a ROCK1-dependent mechanism (Schackmann, van 
Amersfoort et al. 2011). Interestingly, p120 ablation in the same p53 mutant mouse generates tumors 
that are E-cadherin-deficient and metastatic but do not recapitulate the lobular phenotype 
(Schackmann, Klarenbeek et al. 2013)(Hernandez-Martinez, Ramkumar et al. 2019).  The effects of 
p120-ablation, therefore, are not necessarily the same as those caused by the loss of E-cadherin. 
Invasive ductal BC (IDC) is by far the most common BC subtype, accounting for ~80% of all human 
BC. Of note, p120 downregulation occurs in over 50% of IDC (Sarrio, Perez-Mies et al. 2004) and 
has been linked to poor prognosis (Nakopoulou, Gakiopoulou-Givalou et al. 2002, Talvinen, Tuikkala 
et al. 2010). Two small studies report regions of complete p120 loss in approximately 10% of ductal 
carcinomas (Dillon, D'Aquila et al. 1998, Nakopoulou, Gakiopoulou-Givalou et al. 2002). 
Nonetheless, p120's role in tumor progression and metastasis of IDC remains unclear. 
Using MMTV-Cre; p120f/f mice, we showed previously that p120 is essential for mammary gland 
development. Spontaneous Cre-mediated p120 ablation at the onset of puberty (week 3) results in 
a pool of essentially non-adherent, E-cadherin-depleted cells that are lost altogether by week 6 
(Kurley, 2012). In the present study, we crossed these mice onto an MMTV-PyMT background (i.e., 
MMTV-Cre; p120f/f; MMTV-PyMT) to examine the effect of p120 ablation in the context of a well 
characterized p53-independent mouse model of invasive ductal mammary carcinoma (IDC). 
Oncogenic transformation by PyMT rescued the p120 null population, which in spite of near complete 


































tumors.  The current study reports the outcome of these p120-ablation experiments on tumorigenesis 
and pulmonary metastasis.  
Results
  
Characterization of p120 ablation in the MMTV-PyMT mouse model of breast cancer.  
 To examine the role of p120 in ductal breast cancer metastasis, we crossed our previously described 
mammary-specific p120 knockout mouse (MMTV-Cre; p120fl/fl)(Perez-Moreno, Davis et al. 2006, 
Kurley, Bierie et al. 2012) to a well-characterized MMTV-PyMT mouse model of breast cancer (Lin, 
Jones et al. 2003).   In the experimental cohort from this cross (MMTV-Cre; p120fl/fl; MMTV-PyMT), 
PyMT expression and p120 ablation were induced simultaneously upon activation of the MMTV 
promoter at puberty (~3-4 weeks of age).  We showed previously that in the absence of a 
transforming event, MMTV-Cre-induced p120 null cells were cleared from the developing gland and 
lost altogether by the end of week 6, after which the gland was reconstituted normally from p120-
retaining stem cells (Kurley, Bierie et al. 2012). Here, we show that in the context of PyMT-induced 
transformation, p120-null cells are rescued and retained in primary tumors (Figure 1ABC). 
Depending on the animal, the overall proportion of tumor cells lacking p120 ranged from ~22 - 58% 
(38% average) (Figure 1B). p120 null regions of these primary tumors retained significant Keratin-8 
positivity (Figure 1C), suggesting overall retention of epithelial identity. Surprisingly, mosaic p120 
ablation did not affect primary tumor latency or primary tumor volume (Figure 1D, E), and differences 
in carcinoma cell apoptosis and proliferation were not statistically significant (Figure S1 A, B). 
To assess the overall impact of p120 ablation on the E-cadherin complex, we immuno-labeled p120 
positive and negative tumors with antibodies to E-cadherin and β-catenin (Figure S1C, D). p120 KO 
in the context of mT resulted in nearly complete loss of both E-cadherin and junctional β-catenin, as 
was previously observed in the absence of mT expression (Kurley, Bierie et al. 2012). Loss of the E-
cadherin complex occurs to varying degrees upon p120 ablation as previously demonstrated in many 
epithelial tissues(Davis and Reynolds 2006, Perez-Moreno, Davis et al. 2006, Stairs, Bayne et al. 
2011, Kurley, Bierie et al. 2012) but the mammary gland is unusual in that E-cadherin staining is 
almost abolished by p120 KO.   
 MMTV-PyMT tumors typically display a mix of distinct morphological features during progression. In 
the absence of p120, we observed that hyperplastic p120 negative lesions contained epithelial cells 
with a more rounded morphology and increased intraluminal sloughing (Figure S2A), apparently 
reflecting adhesion defects linked to E-cadherin loss.  In addition, whereas late-stage MMTV-PyMT 
tumors typically contain a roughly even mix of pseudopapillary and characteristic adenocarcinoma 
phenotypes (Chetty and Serra 2008), their p120-null counterparts were almost exclusively 



































p120 ablation blocks pulmonary metastatic colonization 
 To determine the effect of p120 on pulmonary metastasis, we examined whole mounts of lungs from 
control and p120 KO MMTV-PyMT animals that were collected 54 days following initial tumor 
palpation (Figure 2). Notably, metastatic lesions in the p120 KO model were substantially larger 
(Figure 2A; quantified in 2C) and four-fold more numerous (median of 3 in controls compared to 12.5 
in KOs) (Fig. 2B) than those from p120 positive controls, revealing a strong, apparently pro-
metastatic impact of p120 ablation.  Surprisingly, however, immunolabelling experiments revealed 
that the actual pulmonary metastases from p120 KO animals were predominantly p120 positive 
(Figures 2D & 2E).  Examples of the p120 content of individual pulmonary metastases from these 
animals are shown in figure 2D (i.e., positive, mixed, negative).  To document the overall distribution 
of p120 positivity, metastases were scored as entirely positive, mostly positive, mostly negative, or 
entirely negative, and then quantified in each of six randomly selected p120 KO mice (Figure 2E).   
 Of note, entirely p120 negative metastases were exceedingly rare. They manifested in one animal 
only (mouse #6) and comprised only 15% of the total number of lung metastases in that animal (as 
opposed to 70% entirely positive).  By contrast, in two animals (numbers 4 & 5), all of the metastases 
were entirely p120 positive. Moreover, irrespective of the mix, metastases in all six animals 
demonstrated strong selection for p120 positivity. These data suggest that despite the pro-metastatic 
effects of p120 ablation in primary tumors, retention of p120 confers a strong selective advantage 
with respect to establishing distant metastases.   
To identify particular events in the process that might account for this enrichment, we used Cre 
recombinase-based methods to generate matched sets of polyclonal and monoclonal p120 positive 
(WT) and p120 negative (KO) PyMT tumor cell lines (Figure 3). As shown previously in vivo (Figures 
1 and S1), p120 null cells displayed near absent levels of E-cadherin, but retained expression of the 
epithelial marker Keratin 8 (Figure 3A), suggesting retention of epithelial identity. Note that among 
the p120-null cell lines isolated from individual tumors, there were occasional p120 positive cells that 
served as internal positive controls (e.g., Fig. 3A, lower left panel). Interestingly, p120 KO induced 
superficial characteristics of mesenchymal cells (Figure 3A, bright field panels), raising the possibility 
a bone fide EMT. On the other hand, loss of intercellular adhesion following p120 ablation is expected 
to phenocopy many of the effects of EMT.  Although not necessarily definitive, we observed that 
mRNAs typically upregulated by classical EMT (e.g., vimentin, snail, slug, Zeb1, SMA, S1004A) were 
not upregulated in a microarray dataset derived from p120 KO PyMT cells (data not shown). The 
simplest interpretation of these data, therefore, is that the mesenchymal-like phenotype observed is 
instead due to adhesive defects caused by p120 ablation.  
In vivo effects of p120 ablation on tumor initiation and progression were assayed by transplanting 
isogenic p120 positive and negative PyMT cell lines into the cleared mammary fat pads of wild-type 
recipients. Similar to the results observed in the autochthonous mouse models, primary tumor 


































metastases were evident in 77.8% of mice transplanted with p120 positive tumor cells, whereas 
metastases were virtually absent from mice transplanted with the isogenic p120-null counterparts 
(Fig. 3C). Thus, p120 KO in this model had relatively minor effects at the level of the primary tumor 
but almost completely blocked the formation of distant metastases.  
To identify which stage(s) of the metastatic cascade were impaired by p120 loss, we assayed several 
metastasis-associated parameters, comparing MMTV-PyMT-transformed cell lines (controls) to their 
p120 KO counterparts.   Cell motility was examined by an in vitro wound-healing assay.  In the 
presence of p120, "wounded" cell monolayers were closed primarily by a process of collective 
migration.  By contrast, p120 KO cells exhibited primarily single cell migration, which was only 
marginally less efficient (Kurley, Bierie et al. 2012)(Sup Vid).  In vitro invasion assays, on the other 
hand, showed that p120 KO cells were 2 - 10 fold more efficient at penetrating transwell filters coated 
with matrigel, a model extracellular matrix (Figure 3D).  Intravasation and survival in the bloodstream 
is typically assayed by quantification of circulating tumor cells in blood. However, for reasons that 
are unclear, the method is notoriously difficult to reproduce in MMTV-PyMT mouse models (Muraoka, 
Lenferink et al. 2002).  Although we found no statistical difference in the results from control and 
p120-ablated animals, the number of cells isolated were typically low and highly variable in both 
cohorts (Supp. Fig. S3A and B).  Taken together, however, these data suggest that p120-ablation 
enhances several mesenchymal cellular characteristics, including fibroblast-like morphology, a 
transition from collective- to single-cell migration, and a marked increase in invasive behavior, 
alterations likely to be pro-metastatic with respect to the early steps in the metastatic cascade. 
          As mentioned, generally acknowledged properties associated with metastatic capacity include 
the ability to (i) intravasate, (ii) survive in the bloodstream, (iii) extravasate, and/or (iv) survive and 
proliferate post-extravasation in effectively hostile foreign microenvironments. To further examine 
the ability of cells to survive in circulation and subsequently extravasate, isogenic p120 positive or 
negative PyMT tumor cells were labeled with a fluorescent dye and injected directly into circulation 
via the tail vein. Intraluminal survival/extravasation and subsequent clearance from the lungs were 
monitored by fluorescence microscopy at 1- and 6-hour time points, respectively (Supp. Fig. S3 C). 
p120 ablation, however, did not affect the number of cells retained in the lung at either time point, 
suggesting that p120 KO does not substantially alter the kinetics of extravasation and/or the 
subsequent clearance from the lung.  
 
In the metastatic cascade, progression from disseminated micrometastases to clinically relevant 
macrometastatic lesions, is referred to as metastatic colonization. We postulated that p120 might be 
essential for (i) formation/survival of micrometastatic lesions, or alternatively, (ii) for the outgrowth of 
established micrometastases into macroscopic secondary tumors. To test the hypothesis, isogenic 
p120 positive or negative PyMT cell lines were tail vein injected and assayed 21 days later for 


































positive) formed large numbers of macrometastatic lesions while their isogenic p120 KO counterparts 
were completely deficient in this process.  
To clarify the underlying mechanism(s), we conducted soft agar colony formation assays to 
determine whether p120 KO cells were capable of anchorage-independent cell growth, an in vitro 
surrogate for tumorigenicity.  We found that p120 ablation eliminated an otherwise robust ability of 
WT PyMT cells to undergo anchorage-independent cell growth. Thus, p120-loss in PyMT 
transformed cells confers a cell-intrinsic anchorage-independent growth defect that may be related 
to its in vivo defect in pulmonary colonization (Fig. 3E).    
p120-dependent regulation of the primary tumor microenvironment  
Paradoxically, although p120-ablation markedly increased the size and number of pulmonary 
metastases, the actual metastatic lesions were almost invariably p120 positive. A potential 
explanation is that the p120-ablated component of primary PyMT tumors might indirectly promote a 
significant pro-metastatic microenvironment.  For example, p120 ablation in some tissues (e.g., skin, 
esophagus) leads to cell-autonomous inflammation that has been causally linked to tumorigenesis 
(Perez-Moreno, Song et al. 2008, Stairs, Bayne et al. 2011).  Thus, we interrogated the primary 
tumor microenvironments from cohorts of PyMT and PyMT/p120 KO mice (Fig. 4).  Notably, 
significantly increased abundance of macrophages (F4/80 positive) and myofibroblasts (SMA 
positive) were observed in regions of p120 ablation (Figures 4A and 4B, respectively).  Trichrome 
blue staining indicated higher levels of collagen deposition in the p120-null tumors (Fig. 4C).  Other 
cell populations within the primary tumor microenvironment, including several types of vasculature 
and CD3+ T-cells, were consistent between the two models (Figure S5 A-C). Overall, these data 
illustrate distinct alterations in the tumor stroma associated with p120-ablated epithelium.  
 To further characterize the primary tumor microenvironment, we analyzed macrophage infiltration 
and phenotype by flow cytometry and qRT-PCR.  To quantify macrophage recruitment, tumors were 
dissociated and viable cells were analyzed by flow cytometry using antibodies that collectively detect 
macrophages (CD45+, CD11b+, F4/80+).  By this method, total macrophage numbers were 
unaltered in PyMT p120 KO mice (data not shown). Thus, F4/80 positive macrophage populations 
observed in figure 2A may reflect locally enhanced recruitment to regions of p120 ablation, as 
opposed to the whole tumor. Macrophages exist in a variety of phenotypic states, including anti-
tumor M1 and pro-tumor/pro-metastasis M2 (DeNardo and Coussens 2007).  By flow cytometry using 
well-established M1 and M2 markers, the proportion of M1-like tumor macrophages were similar in 
p120 WT and p120 KO samples. However, M2 macrophages, were significantly increased in p120 
knockout tumors (Figure 4D), suggesting a pro-tumor/pro-metastasis bias.  To assess transcript 
levels, RNA from flow-sorted populations of CD45+CD11b+F4/80+ tumor macrophages was 
assessed by RT-qPCR analyses. Results from this analysis revealed significantly increased Mmp2 
and Mmp9 (M2-like markers), and decreased M1-like markers TNFα, and IL12β (Figure 4E), 


































progression. Therefore, we postulated that p120-ablated tumor cells might selectively secrete factors 
known to function in the recruitment of macrophages.  Conditioned media from p120-negative PyMT 
cells was 3- to 10-fold more effective in the in vitro recruitment of peritoneal macrophages than media 
from control (p120-positive) cells (Figure 4F). Thus, p120 ablation in the context of PyMT-expressing 
mammary tumor cells elicits secretion of as yet unidentified factors that may account for the activities 
of p120-negative PyMT cells in the recruitment and/or behavior of resident macrophage populations.   
Reduced p120 in primary tumors associates with a less-favorable outcome. 
p120 levels are frequently reduced and sometimes lost altogether in a wide variety of epithelial 
cancer types, including breast (Thoreson, Anastasiadis et al. 2000). To clarify inconsistencies in the 
pathology literature on ductal breast cancer, p120 expression was examined by 
immunohistochemistry in a cohort of 1126 patients with primary invasive ductal breast cancer.  
Details of the patient cohort are provided in Supplemental Table 1. Figure 5A shows representative 
examples of p120 expression in invasive ductal breast cancer corresponding to IHC scores 0 – 3 
(panels i - iv), as compared to normal breast (panel v) and ductal carcinoma in situ (DCIS) stained 
for p63 (panel vi) or p120 (panel vii). High p120 expression (score 3) was observed in 49.7% of the 
primary tumor samples, similar to p120 staining intensity seen in normal breast (score 3) (Fig. 5A, 
Table 1). Complete loss of p120 (e.g., Fig.5A, panel i) was observed in 7.5% of the cases.   
Partial p120 loss (scores 1 and 2) and complete 120 loss (score = 0) correlated with higher tumor 
grade, higher pT stage and estrogen receptor negativity (Table 1). We found no correlations with 
other parameters such as nodal stage and HER2 status, and nearly all DCIS cases (128/129, 99.2%) 
showed strong (score = 3) p120 expression (e.g., Fig. 5A, panel iv,). Staining for p120 was localized 
primarily to plasma membranes, and cytoplasmic p120 expression was observed in only 96/1126 
(8.5%), consistent with previously published data on ductal breast cancer (Sarrio, Perez-Mies et al. 
2004).  
  
Overall, statistical analyses show that reduced or absent p120 in primary invasive ductal breast 
cancer is significantly associated with worse outcome (Figure 5B). By multivariate analysis, p120 did 
not qualify as an independent prognostic factor (compared with pT, grade, pN, and with/without 
estrogen receptor). However, patients with complete or partial loss of membranous p120 expression 
had significantly shortened overall survival in a univariate analysis (p=0.027) (Figure 5B).  Also, 
patients whose tumors showed complete p120 loss (score 0, n=73) versus all other levels (score 1-
3, n=862) at the time of histology had a significantly shorter overall survival (p=0.011).  
p120 loss in distant and/or lymph node metastases is rare.   
Extending the analysis to breast cancer metastatic lesions, we initially examined p120 in 225 lymph 


































metastases (n=225) indicated strong expression in 48.9% of cases (110/225) (score 3), reduced 
expression in 36.9% (83/225) (score 2), weak expression in 12.4% (28/225) (score 1), and absent 
p120 staining in 1.8% (4/225).  In the set of distant (non-lymph node) metastases (n=11), p120 was 
expressed in 100% of cases (45.5% scored 1 or 2, 54.5% scored 3) (Fig. 5C).  
Next, we interrogated a set of metastases from individuals whose primary tumors were p120 
negative. Of the 84 primary invasive ductal breast cancer cases with complete loss of membranous 
p120 staining, 14 cases of matched metastatic disease (16.7%) were available from the archives.  
Of these, 5/14 (35.7%) expressed high levels of p120 (score 3), 5/14 (35.7%) showed reduced levels 
(score = 2), 3/14 (21.5%) scored weakly (score = 1) and one (7.1%) was negative (score = 0) (Figure 
5D).  Thus, despite complete absence of p120 staining in all 14 primary tumors, all but one of the 
metastases were p120 positive, and the majority (10/14) were either normal (5/14, score 3) or 
moderately reduced (5/14, score 2).   
                                                                                                                                                                                 
Discussion  
The vast majority of human BC (~80%) manifests as IDC, as modeled here in MMTV-PYmT mice.  
Downregulation of p120 in IDC is associated with poor prognosis (Saijo, Sato et al. 2001, Wijnhoven, 
Pignatelli et al. 2005), but underlying mechanism(s) are not well understood. Importantly, we found 
that pulmonary metastases obtained from human IDC patients were almost invariably positive for 
p120, even in matched samples where the primary tumors were p120 negative. This seeming 
contradiction is addressed in the current study using mouse models for insight into mechanism and 
human IDC to validate our observations in mice.   
We previously demonstrated that MMTV-targeted p120 ablation during development of the 
mammary gland resulted in completely non-adherent cells that were unable to participate in 
formation of the gland. By six weeks, this non-adherent pool was lost altogether and replaced by 
normal mammary tissue reconstituted from a residual pool of p120-retaining stem cells (Kurley, Bierie 
et al. 2012).  In the current study, we used the MMTV-mT mouse model to directly examine the 
effects of mosaic p120 ablation in the context of a transforming oncogene. Indeed, transformation by 
PyMT rescued the viability of a p120-negative pool that otherwise did not survive.  Unexpectedly, 
however, the absence of p120 did not exacerbate metastasis, but rather suppressed the strong 
metastatic proficiency normally conferred by PyMT.  
Collectively, our results suggest a strong selective pressure for retention of p120 during metastatic 
colonization of distant sites. To validate this hypothesis experimentally, we generated isogenic mT-
transformed cell lines differing only by the presence or absence of p120.  Notably, in orthotopic 
implantation experiments, the absence of p120 had little impact on primary tumor latency or volume, 
as observed initially in the autochthonous model, but metastasis was abolished. This effect was 


































that bypasses the primary tumor altogether to pinpoint activities that are selectively relevant to the 
colonization of distant sites. Remarkably, p120-ablated cell lines exhibited no evidence of 
colonization, whereas their p120 expressing parental counterparts were aggressively metastatic. 
Consistent with these data, p120-ablation also eliminated an otherwise robust ability of these cells 
to undergo anchorage-independent cell growth. Thus, expression of p120 in these mT-transformed 
cell lines is apparently required for anchorage-independent growth, and importantly, for distant 
metastatic colonization. 
This requirement for p120 during metastatic colonization is most- likely explained by its essential role 
in maintaining E-cadherin stability. Despite E-cadherin's reputation as a potent metastasis 
suppressor, compelling evidence suggests that several modes of metastatic dissemination and or 
colonization may actually depend on the expression or re-expression of E-cadherin. In general, 
models to this effect fall into one of two main categories. The first invokes metastatic dissemination 
by collective migration      (Huang, Jolly et al. 2015, VanderVorst, Dreyer et al. 2019) (Cheung and 
Ewald 2016), a process known to require p120 and its stabilizing effect on E-cadherin (Macpherson, 
Hooper et al. 2007, Kota, Terrell et al. 2019, Gritsenko, Atlasy et al. 2020).  The second invokes 
dissemination via an epithelial to mesenchymal transition (EMT), which confers a spectrum of 
mesenchymal traits that enable and/or promote metastatic behavior (e.g., exchange of E-cadherin 
for N-cadherin, mesenchymal cell morphology, invasive behavior, cancer stem cell properties, 
anchorage-independence) (Jones, Wang et al. 2014, Hernandez-Martinez, Ramkumar et al. 2019).  
Importantly, EMT is reversible, and several lines of evidence  suggest that successful metastatic 
colonization following dissemination by EMT depends ultimately on the reversal of this process (i.e., 
mesenchymal to epithelial transition / MET), as evidenced in part by frequent re-expression of E-
cadherin in distant metastatic lesions (i.e., MET) (Wells, Yates et al. 2008, Brabletz 2012, 
Gunasinghe, Wells et al. 2012). A third model suggested recently by Ewald and colleagues poses 
an essential role for E-cadherin as a survival factor (Padmanaban et al., 2019).  Absent E-cadherin, 
an apoptotic 
response to conditions imposed by the metastatic cascade.  Notably, all of these models ultimately 
posit essential roles for E-cadherin that are p120-dependent.  
A hallmark of classic EMT (and partial manifestations thereof) is the upregulation of a mesenchymal 
cadherin (usually N-cadherin) at the expense of E-cadherin, whose expression is simultaneously 
reduced or lost altogether.  The mesenchymal properties of N-cadherin are closely associated with 
increased cell motility, invasion, and other aspects of metastatic dissemination (Thiery, Boyer et al. 
1988, Gritsenko, Atlasy et al. 2020).  Like most, if not all, classical cadherins, however, the stability 
of N-cadherin is also p120-dependent. Thus, in the context of EMT-mediated metastatic 
dissemination, p120 ablation might conceivably impair early events in the metastatic cascade via 
destabilization of N-cadherin, and/or late events (e.g., MET, colonization), via destabilization of E-


































not necessarily mutually exclusive (Thiery, Boyer et al. 1988, Wagner, Roderburg et al. 2007, 
Theveneau and Mayor 2012, Peglion, Llense et al. 2014).  
These observations are important because dysregulation of E-cadherin function and/or expression 
to varying degrees is evident in the vast majority of human cancer, 90% of which is epithelial in origin. 
The effects are generally interpreted in the obvious context of adhesion.  However, our findings 
suggest that p120 and/or E-cadherin dysfunction may have other important consequences, including 
pro-metastatic conditioning of the tumor microenvironment, that are not yet fully appreciated.  
Moreover, this is not the first report of significant adverse consequences to the microenvironment 
associated with conditional p120 ablation.  Although effects vary widely, depending on the tissue, 
p120 ablation in the skin (Perez-Moreno, Davis et al. 2006) or the esophagus (Stairs, Bayne et al. 
2011) have significant inflammatory effects that appear to be causally linked to tumorigenesis.  The 
possibility that such effects contribute significantly to the immune and microenvironmental conditions 
underlying tumorigenesis remains largely unexplored. 
Though paradoxical at face value, our data are consistent with the notion of distinct roles for p120 at 
different stages of the metastatic cascade. In the mouse model used herein (MMTV-mT; MMTV-Cre; 
p120fl/fl), MMTV is activated around three weeks of age and controls both the tumor-initiating event 
(i.e, expression of mT) and the timing of p120 ablation (via upregulation of Cre), which occur more 
or less simultaneously. Thus, p120-ablation is, by definition, a very early event in this model that 
clearly increases both the number and size of p120-positive pulmonary metastatic lesions. 
There are two general models relevant to the nature and timing of metastatic dissemination (Peglion, 
Llense et al. 2014, VanderVorst, Dreyer et al. 2019) (Huang, Jolly et al. 2015, Kota, Terrell et al. 
2019). The "linear" progression model posits that metastasis-competent subclones arise late in tumor 
progression due to accumulation over time of genetic and epigenetic alterations.  According to this 
model, metastases typically develop from aggressive late-stage subclones of the primary tumor and 
therefore share, at least initially, the same spectrum of genetic alterations.  For example, if loss of 
p120 (or E-cadherin) were to trigger metastasis directly, one might expect this event to be reflected 
in the actual metastases, but that is not what we observed.  p120 null cells were almost entirely 
excluded from metastatic lesions. This result is particularly striking in experiments where the early 
stages of metastasis are bypassed altogether by introducing the p120 null cells directly into the blood 
via tail vein injection.  
In contrast, the "parallel" progression model suggests that metastatic dissemination is an early event 
and that primary and metastatic clones evolve independently thereafter. Loss of E-cadherin, for 
example, is typically viewed as a late event in tumor progression and a key mediator of the transition 
to metastasis.  In our experiments, however, deletion of p120 was, by definition, an early event, and 
the metastatic lesions exacerbated by this event did not contain this mutation.  Thus, we suggest 
that the early effects of p120 ablation with respect to successful metastatic colonization are not cell 


































indirectly at the level of the primary tumor, most likely functioning to accelerate dissemination of p120 
expressing cells. Thereafter, retention of p120 becomes a major discriminating factor with respect to 
successful metastatic colonization. 
We showed recently in Adenomatous Polyposis Coli (Apc) mouse models of intestinal cancer that 
loss of one p120 allele dramatically increases tumor multiplicity.  Surprisingly, however, loss of the 
second allele did not further enhance tumorigenesis, but rather turned out to be synthetic lethal with 
loss of Apc. Thus, complete loss of p120 was never observed in these Apc-LOH-initiated tumors 
because intestinal stem cells exhibiting loss of both proteins were rapidly eliminated (Short, Kondo 
et al. 2017, Short, Barrett et al. 2019). This phenomenon applies to α-catenin and E-cadherin as well, 
providing a compelling explanation for why complete loss of E-cadherin function is almost invariably 
a late event in intestinal cancer.  These observations clearly imply the existence of a failsafe 
mechanism that somehow restricts complete loss of E-cadherin function during the early stages of 
intestinal tumor formation. Complete loss of E-cadherin function does, however, occur in late-stage 
tumors, suggesting that the failsafe mechanism(s) itself eventually fails as tumors progress to 
malignancy.  
In closing, it is worth mentioning that retention of p120 (and E-cadherin) at distant metastatic sites 
was surprising, in part, because E-cadherin is widely viewed as a metastasis suppressor. By any 
conventional interpretation of the literature, one would expect metastases promoted by p120-ablation 
to be comprised largely, if not entirely, of p120-negative (E-cadherin-deficient) cells. Instead, our 
results reveal a strong selective pressure for p120 retention and are largely in line with a rapidly 
emerging literature on E-cadherin.  In particular, it is increasingly clear that several modes of 
metastatic dissemination and/or colonization are dependent on the expression or re-expression of 
E-cadherin. One example is metastatic dissemination by collective migration   (Huang, Jolly et al. 
2015, VanderVorst, Dreyer et al. 2019) (Cheung and Ewald 2016), a known p120 and E-cadherin 
dependent process (Macpherson, Hooper et al. 2007, Kota, Terrell et al. 2019, Gritsenko, Atlasy et 
al. 2020). Remarkably, all of these dedicated metastatic processes are partly, if not wholly, 
dependent on the so-called “metastasis suppressor”, E-cadherin. Our data and conclusions by 
enlarge are in line with related evidence published recently by Ewald and colleagues for E-cadherin 
(Padmanaban et al., 2019).  
 
Materials and Methods 
Patient cohort and tissue samples 
A cohort of clinically characterized breast cancer patients with primary invasive ductal cancer 
diagnosed from 1991-2005 at the University Hospital Zurich was enrolled in the tissue microarray 
(TMA) study as described elsewhere (Theurillat, Ingold et al. 2007). Tumor grade was performed 


































cohort, invasive ductal carcinomas were studied.  For clinicopathological parameters, see 
supplemental Table S1. Because 10% of the patients were followed-up >120 months, follow-up time 
was censored in all survival analyses presented in this article. The study was approved by the ethical 
committee of the Kanton of Zurich (reference number StV-12-2005).  
Immunohistochemistry on Patient Samples 
 All antibodies were tested on a multi-tissue TMA for appropriate dilution and were used in a 
diagnostic protocol. Monoclonal antibodies to anti-p120 (BD Bioscience, clone 98/pp120, 1:200), and 
anti-E-cadherin (Cell Marque Lifescreen Ltd., Rocklin, CA, USA, clone EP700Y, 1:200), anti-Ki-67 
(Dako, Glostrup, Denmark, clone MIB1, 1:20), anti-p63 (Thermo Scientific  Lab Vision, Thermo 
Scientific, 4A4+Y4A3 (63P02), 1:200) were used. All immunohistochemical stains were performed 
on a Ventana Benchmark® platform (Ventana Medical Systems, Tucson, AZ, USA). The CC1 
standard pretreatment with 60 min boiling in pH 8 Tris buffer (Ventana) was followed by incubation 
with primary mAb (dilution 1:200) for 60 min at room temperature (RT) and development with the 
Ultraview-HRP kit (Ventana/Roche), including incubation with respective secondary antibody for 30 
min at RT. P120 antibody was diluted in Tris/BSA. For counterstains, hematoxylin was used. P120 
immunoreactivity at the tumor cell membrane was semi-quantitatively evaluated applying a four-
tiered system (score 0 negative, score 1-weak discontinuous expression, score 2-moderate 
continuous expression, and 3 score-strong continuous expression). Cytoplasmic p120 staining was 
scored as negative (score 0), weak (score 1), moderate (score 2) and strong (score 3). Scoring was 
done by three experienced pathologists (A. N., Z. V., V. T). Normal breast glands served as positive 
internal control and a standard for score 3. E-cadherin was evaluated at the tumor cell membrane as 
positive (strong expression) and negative (partial or complete loss of expression) cases (S. B.) 
Estrogen receptor status and HER2 FISH analysis were performed as described elsewhere 
(Theurillat, Ingold et al. 2007). 
Animals 
To generate mammary-specific p120 KO mice, p120f/f mice were backcrossed onto an FVB/NJ 
background and crossed with MMTV-cre#7 obtained from Dr. Muller on an FVB background 
(Andrechek, Hardy et al. 2000), (Andrechek, White et al. 2005, Perez-Moreno, Davis et al. 2006, 
Kurley, Bierie et al. 2012). p120 ablation in a mouse model of breast cancer was achieved by 
crossing the mammary-specific p120 KO mice with an FVB backcrossed version of MMTV-Polyoma 
Middle T (PyMT) model (Guy, Cardiff et al. 1992).  All experiments involving animals were approved 
by the Vanderbilt University Institutional Animal Care and Use Committee. 
Immunohistochemistry/Immunofluorescence on mouse samples 
Fluorescent Immunostaining on tissue was performed as previously described (Perez-Moreno, Davis 
et al. 2006, Kurley, Bierie et al. 2012).  Briefly, tissues were fixed in 10% formalin. Paraffin-embedded 


































in 10 mM Sodium Citrate pH 6.0 for 10 minutes. After blocking, slides were incubated in primary and 
secondary antibody overnight and for 2 hours, respectively. Primary antibodies against the following 
were utilized: p120 (F1αSH 0.8μg/mL), E-cadherin (0.5 μg/mL, BD Biosciences), β-catenin (1:800, 
Sigma-Aldrich), Keratin 8 (TROMA-I 1:1000 0.2μg/mL University of Iowa Hybridoma Core), F4/80 
(1:200, AbDSerotec- requires trypsin antigen retrieval), SMA (0.2μg/mL Sigma-Aldrich), Meca32 
(1:100, BD Biosciences). Secondary antibodies (1:500, Invitrogen) were conjugated to either Alexa 
dye 488, 594, or 647.  Sections were mounted with Prolong Gold Antifade Mounting Medium 
(Invitrogen, Carlsbad, California, USA). Tissue processing, hematoxylin and eosin (H&E) staining, 
and immunohistochemsitry for CD31 (1:100, Dianova) and CD3 (1:600, Santa Cruz Biotechnology) 
was performed by the Vanderbilt Translational Pathology Shared Resource Core. TUNEL staining 
assays were performed as per the manufacturer's instructions with the following modification: antigen 
retrieval for 10 minutes in proteinase K (Millipore, Danvers, Massachusetts, USA).  Staining was 
visualized using an Axioplan 2 microscope (Zeiss, Oberkochen, Germany). Images were collected 
with either an Olympus QColor 3TM digital camera or a Hamamatsu Orca ER fluorescent camera 
and processed using MetaMorph software. 
Cell Immunofluorescence 
 Cells were plated on glass coverslips and fixed in 3% paraformaldehyde for 30 minutes. After PBS 
washes, cells were permeabilized in PBS with 0.2% TritonX-100 for 5 minutes. After more PBS 
washes, non-specific binding was blocked using PBS with 3% nonfat milk. Cells were incubated in 
primary antibody for 30 minutes, washed, and incubated in secondary antibody for 30 minutes. After 
3 PBS washes, nuclei were stained using Hoechst dye. Coverslips were coated in ProLong gold 
(Invitrogen) and mounted on glass slides. Quantification of staining was assessed in n=6 mice per 
genotype, 1 section encompassing random pieces of tissue, six images per section. When possible, 
p120 negative regions for KO animals were determined using co-IF.  
Generation and Manipulation of PyMT-derived Cell Lines 
Tumor tissue was collected under sterile conditions, minced into 1mm size pieces, and incubated in 
digest media [DMEM:F12, 1% antibiotic/antimycotic, 100 units/mL hyaluronidase, 3 mg/mL 
collagenase A, gentamycin] for 3-4 hours with agitation at 37°C. Cells were pelleted at 1000 RPM 
and washed 5 times in PBS supplemented with 5% adult bovine serum. Fibroblasts were removed 
by resuspending the pellet in low serum media and plating the material on a sterile petri dish. After 
1 hour in the incubator, cells not attached to the dish were spun down and resuspended in full growth 
media [DMEM:F-12, 5% adult bovine serum, insulin, progesterone, 17-b-estradiol, EGF, 1% 
antibiotic/antimycotic, gentamicin]. Cells were plated onto collagen-coated plates and allowed to 
adhere for 48 hours before media changing. Cell lines were established by passaging cells at least 
15 times prior to experimental use after which point they were grown in DMEM supplemented with 


































lentiviral constructs expressing non-targeting shRNA (control) or Cre-recombinase (p120 KO) and 
then cells were selected for by puromycin treatment.   
Wound Healing Assays 
 PyMT-derived cells were plated to confluence and scratched with a P200 tip to generate the wound. 
Cells were rinsed with PBS, covered in growth media, and imaged at six regions per scratch every 
6 hours. Images were acquired using an Axiovert 200M microscope (Zeiss) and processed using 
MetaMorph software.  
Transwell Invasion Assays 
 Matrigel-coated transwells were equilibrated by the manufacturer's instructions. Cells were then 
plated in serum-free media in the top well and promoted to invade toward 10% media in the bottom 
chamber. After 24-48 hours, transwells were fixed and stained using a Diff-Quik staining kit 
(Allegiance). Ten random fields of view per transwell were analyzed.  For macrophage invasion 
assays, intraperitoneal injections with 2 mL thioglycolate were performed using a 27G needle.  After 
4 days, the abdominal cavity was filled with PBS, and peritoneal macrophages were isolated. 
Macrophages were pelleted and resuspended in serum- free media and immediately used for 
invasion assays as described above. To generate the stimulus for macrophage invasion, PyMT-
derived cells were grown in 3D matrigel cultures for at least seven days. Serum-free media was 
added to the cultures, collected after 24 hours, and used for invasion induction of macrophages.  
Western Blot Analysis 
Protein was isolated as previously described (Mariner et al., 2004). Briefly, cells were washed with 
PBS, lysed in RIPA buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1%Nonidet P-40, 0.5% Deoxycholic 
Acid, 0.1% sodium dodecyl sulfate] containing inhibitors [1mM phenylmethylsulfonyl fluoride, 5 
μg/mL leupeptin, 2 μg/mL aprotinin, 1mM sodium orthovanadate, 1mM EDTA, 50mM NaF, 40mM B-
glycerophasphate] and spun at 14,000g at 4°C for 5 minutes. Cleared total protein was quantified 
using a bicinchoninic acid assay (Pierce, Rockford, Illinois, USA). 20 μg of protein per sample were 
boiled in 2X Laemmli sample buffer and separated by SDS-polyacrylamide gel electrophoresis. 
Proteins were transferred to nitrocellulose (PerkinElmer, Waltham, Massachusetts, USA). Non-
specific binding was blocked by incubating membranes in 3% nonfat milk in Tris-buffered saline and 
Odyssesy blocking buffer (LI-COR, Lincoln, Nebraska USA) prior to the addition of primary and 
secondary antibodies, respectively. Anti-p120/pp120 (0.1μg/mL, BD Biosciences), anti-E-cadherin 
(0.1μg/mL, BD Biosciences), anti-tubulin/DM1α (1:1000, Sigma-Aldrich), anti-N-cadherin (0.8μg/mL 
13A9, Millipore), and anti-P-cadherin (1:250, BD Biosciences) antibodies were used. The Odyssey 





































1X106 cells were suspended in 50 μL of 1:1 type I collagen (1.19 mg/mL final concentration) to 
neutralization solution [100mM Hepes in 2X PBS pH 7.3]. Plugs were allowed to solidify for 1 hour 
in the incubator and then covered in growth media. The following day plugs were transplanted into 
the cleared fat mammary fat pads of 3 week-old female mice. Tumor growth was assessed by caliper 
and tumors and lungs were collected 5 weeks after transplant. 
Tail Vein Injections and Lung Whole Mount 
PyMT-derived cells were trypsinized, pelleted, and washed 3 times in PBS.  After passage through 
a 70μM strainer, 1x106 cells per 100 μL were injected into the tail vein of mice. After four weeks, 
mice were sacrificed, and lungs were collected. Lungs were analyzed by whole mount and tumor 
burden analysis. Tumor burden was quantified as a percent of metastases area to total lung area at 
three depths per lung. For lung whole mount, lungs were inflated with formalin and fixed overnight. 
Lungs were then dehydrated in progressive increasing amounts of ethanol and cleared overnight in 
Histoclear. Rehydration the next day was followed by staining in Mayer's hematoxylin. After destain 
steps in 1% HCl solution and water, lungs were dehydrated and cleared once again. Analysis of lung 
metastases was performed using a dissecting scope and an Olympus QColor 3TM digital camera.  
Whole Tumor  
Tumors were collected, minced, and incubated in digest media [RPMI with 1 mg/mL collagenase I, 
1 mg/mL dispase II] for 2 hours at 37°C. Tumor material was then pressed through a 70 μM cell 
strainer in 10 mL cold PBS and repeated for a total of 50 mL PBS. Tumor cells were then treated 
with 10 μL of 5MU/mL DNAseI for 5 minutes at room temperature. Cells were pelleted at 300g to 
remove DNAse treatment. Red blood cells were removed from tumor preparations using lysis buffer. 
Cells were washed with PBS, strained, and then counted in the presence of trypan blue. Each sample 
of 5x10^6 cells per 100 μL flow buffer [PBS, 0.5% BSA, 2mM EDTA] was treated with Fc block and 
then incubated in antibodies conjugated to compatible fluorophore combinations for 30 minutes on 
ice. All antibodies were purchased through eBioscience.  After 2 washes with flow buffer, cells were 
analyzed by flow cytometry by the Vanderbilt Flow Cytometry Shared Resource Core. 
Anchorage Independent and 3D Matrigel Growth 
 For anchorage-independent growth assays, six well-dishes were coated with a layer of 0.7% low 
gelling temperature agarose. 5x10^3 PyMT-derived cells suspended in 0.35% agarose were plated 
per well and covered in 2 mL growth media. After 3.5 weeks of growth, colonies were imaged using 
an inverted microscope. For 3D growth assays, 35 mm tissue culture dishes were coated with 500 




































qRT-PCR on Macrophages  
Total RNA was extracted from sorted CD45+CD11b+F4/80+ cells from tumors of d54 PyMT control 
and p120 KO mice (n=3 per genotype) using QIAshredder columns and RNeasy mini kit (Qiagen). 
cDNA was synthesized using Invitrogen Superscript Firststrand synthesis system for RT-PCR 
(Invitrogen). Primers specific for iNOS, TNFα, IL-12, IL-6, IL-1b, VEGF, MMP2, MMP9, MMP13, 
CXCL1, and IL-10 were used and the relative gene expression was determined using ABI PRISM 
7900HT Sequence Detection System (PE Applied Biosystems). The comparative threshold cycle 
method was used to calculate gene expression normalized to β actin. 
Circulating Tumor Cell Assays 
 Fifty-four days after initial palpation mice were euthanized (n=4 per genotype) and whole blood was 
collected in a heparinized needle. Each well of a 6-well dish was coated in 1:1 mix of Matrigel and 
DMEM supplemented with 10% FBS. After Matrigel solidification, 500 μL of whole blood was plated 
per 6-well dish and covered in 2 mL media. After 48 hours, cultures were washed with PBS. Red 
blood cells were removed with lysis buffer [155 mM NH4Cl, 12mM NaHCO3, 0.1 mM EDTA] and 
then washed away with PBS. Colonies were then allowed to grow for 7-10 days with media changes 
every 3-4 days. Colonies were counted in 5 random 2.5x fields and 10 random 10x fields.  For qRT-
PCR experiments, RNA was isolated from whole blood and RT-PCR assays conducted were 
performed as previously described (Connelly et al., 2011).                                                                                     
Statistical Analysis 
Statistical analyses for non-clinical data were performed using GraphPad Prism (GraphPad La Jolla, 
California, USA) as described in figure legends. For assays with or without normal distribution, two-
tailed Student’s t-tests or Mann-Whitney tests were performed, respectively.  For clinical samples, 
associations of staining intensity with clinicopathological parameters were done by descriptive 
statistics (cross tables, two-tailed Fisher's exact test, and two-tailed χ2 test for trends (linear-by-
linear). For correlation significance between immunohistochemical and fluorescence in-situ based 
markers, Kendall’s tau b for non-parametric correlations was used. P-values<0.05 were considered 
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Figure 1: Latency and tumor volume are not altered by mosaic ablation of p120 in PyMT-induced 
mammary tumors 
 
(A-C) Characterization of p120 status in tumors from control (MMTV-PyMT; MMTV-Cre) and p120 
KO (MMTV-PyMT; MMTV-Cre; p120fl/fl) mice. The p120 KO MMTV-PyMT p120 status in knockout 
and control mice was assessed by Western blotting and immunofluorescence. The proportion p120 
KO cells in primary mammary tumors was estimated by p120 immunofluorescence staining of tumors 
from eight MMTV-Cre; p120fl/fl; MMTV-PyMT mice euthanized 54 days post palpation. Each point 
represents the percentage of carcinoma cells exhibiting p120 ablation averaged across three 
sections of random tumor sample per mouse. (D) Control and p120 ablated mice were monitored for 
tumors by palpation (n=21 WT blue, n=23 p120KO red). This n of >20 gives sufficient power (~90%) 
to detect significant differences. No difference in latency was observed using a log-rank test. (E) The 
volumes of all ten mammary tumors per mouse were approximated by calipering (h*l*w = approx. 
volume) at 54 days post palpation. Average volumes per mouse are shown. Error bars = standard 






































Figure 2. Primary tumor p120 ablation increases quantity and size of pulmonary metastases while 
selecting against p120 null cells 
 
(A) Representative metastasis size is shown in lung sections stained with H&E. (B) Visible (surface) 
lung metastases were quantified by Hematoxylin staining performed on cleared lung whole mounts 
removed 54 days post tumor palpation. Mann-Whitney test *p<0.05 (C) Metastasis size was 
measured on lung sections stained with H&E. and binned into the described sizes. n=8 PyMT Control 
and n=12 PyMT p120KO mouse lungs were analyzed (D, E) Lungs from PyMT p120 knock out mice 
were stained for p120 and keratin 8 by immunofluorescence. After identification of PyMT cells by 
keratin 8 positivity, lung metastases were analyzed for p120 status. (D) Representative examples of 
pulmonary metastases stained for p120 and keratin 8. Collective binning data from 91 metastases 
from 6 PyMT p120KO mice are show (E) All visible metastases from n=6 PyMT p120 KO mice 
were assessed and binned into positive (white), mostly positive (light grey), mostly negative (dark 





































Figure 3. p120 ablation induces invasion but blocks pulmonary colonization 
 
Cell lines were generated from MMTV-PyMT; p120f/f mice and were infected with empty or Cre 
expressing retrovirus to generate control or KO cells. (A) Co-immunofluorescence for p120, E- 
cadherin, and Keratin 8 confirms a predominantly p120 negative, keratin positive polyclonal 
population. KO cells are fibroblastic on plastic compared to cobblestone, epithelial control cells as 
evidenced by bright field imaging. (B) 1x106 polyclonal cells expressing empty or Cre-recombinase 
vector were injected into the orthotopic site. Tumor growth of control and p120 KO cells transplanted 
into the orthotopic site of nude mice was monitored by calipers. (C) After 5 weeks, pulmonary 
metastases were assessed by H&E staining of lung sections. Control cells, but not KO cells 
metastasize to the lungs when transplanted into mammary glands of nude mice. Representative H&E 
stained sections of pulmonary tissue are shown above. The arrow denotes a metastasis. (D) In vitro 
invasion assays were performed using three independently derived PyMT cell lines (2 monoclonal 
and 1 polyclonal) infected with control or Cre lentivirus. Ten random fields of view per transwell were 
assessed after 36 hours. Student’s t-test *p<0.001. Assays were performed two independent times 
and a representative graph is shown. (E) PyMT-derived cell lines were grown in agar for 3.5 weeks. 
Representative images at 2.5x magnification are shown. Quantification of growth in soft agar from 
two independent experiments is represented as average number of colonies per full field +/- standard 


































injected into the tail veins of female mice and assayed for lung tumor burden after 4 weeks. (F) 
Quantification of tumor burden in H&E stained sections. Mann-Whitney *p<0.01. Representative lung 





































Figure 4. p120 ablation induces infiltration of M2 macrophages 
 
(A-C) PyMT tumor sections were immuno-stained for F4/80 (A) or SMA (B) to detect macrophages 
and myofibroblasts, respectively. Nuclei are stained with Hoechst dye. To detect collagen, sections 
were stained with trichrome blue (C). n=6 mice per genotype with 6 random 20x images per single 
section were assessed. Mann-Whitney test: ***p<0.0001, **p<0.01. White bars are PyMT Control 
and black bars are PyMT p120 KO. Three regions of random tumor sample per mouse were assayed 
(n=5 per genotype) (D) Flow cytometry analysis of CD45+CD11b+F4/80+ cells in tumor tissue for 
cell surface markers of M1 (top, CD80+CD86+) and M2 (bottom, CD206+CD204+) phenotype. 
Representative FACS plots of macrophage numbers in tumor tissue. Plots are gated as 
CD45+DAPI-. Mann Whitney *p>0.05  . 
 (E) Quantitative RT-PCR on CD45+CD11b+F4/80+ cells from PyMT Control and PyMT p120 KO 
tumor tissues sorted by FACS Aria and converted to cDNA. Data are shown as fold over control. 
(F)  Macrophage invasion assay.  Monoclonal or polyclonal-matched PyMT-derived cell lines were 
grown in 3D cultures.  After establishment of colonies, serum free media was added and collected 


































Macrophages were allowed to invade for 48 hours toward control or p120 KO cell secreted media.  
This graph is representative of two replicates. 10 fields per transwell were assessed for number of 





































Figure 5. p120 expression in invasive breast cancer metastasis 
 
(A) Representative examples of p120 expression in invasive ductal breast cancer (scores 0-3), 
normal breast glands and DCIS (p63 staining for myoepithelial cells) using IHC. (B) Kaplan-Meier 
curve illustrates a significantly shorted overall survival (censored at 120 months) for the patient group 
with altered p120 expression (“p120 low” scores 0-2) compared to “p120 high” expression (score 3), 
p=0.027. (C) Distribution of p120 negative samples by location of source tissue. (D) Representative 
IHC images of p120 negative samples (n=14) and matched metastatic disease. Graph denotes 







































Figure S1: Further characterization of primary tumors from PyMT p120 KO mice. (A) To assess 
proliferation, PyMT tumors were stained for phosphorylated histone H3 by immunofluorescence. (B) To 
assess apoptosis, TUNEL was performed on PyMT tumors. The percent of positive nuclei was assessed in 
3 different pseudopapillary regions per n=6 tumors  of each genotype. No significant difference in rates of 
proliferation or apoptosis was observed using Mann-Whitney tests. All scale bars = 50 μM. (C, D) 
Representative PyMT and PyMT p120 KO tumors were co-immuno- stained for p120 and E-cadherin or 
p120 and β-catenin. Scale bars = 50 μM. 



































Figure S2: p120 ablation results in cell rounding in hyperplastic ducts and a pseudopapillary phenotype 
(A) Early lesions. Sections from control and p120 KO tumors were imaged after hematoxylin and eosin 
staining or IHC for p120. (B) Late stage lesions. Sections were imaged after hematoxylin and eosin 
staining or IHC for p120. While control mice exhibited both solid and pseudopapillary regions, p120 
loss was solely pseudopapillary. 



































Figure S3. p120 ablation does not alter circulating tumor cell amounts or luminal survival/
extravasation kinetics 
(A) CTC Colony forming assay. Whole blood collected from late stage PyMT mice (n=7 Control and n=5 
p120 KO) was plated on matrigel and colony formation from circulating tumor cells was assessed. Graph 
depicts number of colonies per 2.5x field. Mann-Whitney test ns= no significance. Representative 
images of colonies are shown. (B) qRT-PCR Analysis of CTC PyMT expression. RNA 
from blood of late stage PyMT mice (n=3 per genotype) was assessed for PyMT transcript expression. 
Data are presented relative to GAPDH control. Mann-Whitney test ns= no significance. (C) Fluorescently 
labeled PyMT-derived cells were injected into the tail veins of mice (n=3 per cell line and time point) and 
quantified by lung whole mount after 1 or 6 hours. Data are average with error bars of standard deviation. 
Percent loss of fluorescent signal from 1 to 6 hours for each clone is stated. Representative images are 
shown. Scale bars = 100uM. 



































Figure S4: Unchanged events to the tumor microenvironment after p120 ablation 
(A) p120 ablation did not change the following tumor microenvironmental events. PyMT tumors were 
immuno-stained for Meca-32 to detect endothelial cells. Nuclei are stained with Hoechst dye. IHC 
for CD31 and CD3 was used to detect endothelial and T-cells, respectively. Mann-Whitney test: ns= 
no significance. White bars are PyMT Control and black bars are PyMT p120 KO. (B) Representative 
FACS plots of macrophage numbers in tumor tissue. Plots are gated as CD45+DAPI- .Flow 
cytometry analysis of CD45+CD11b+F4/80+ cells in tumor tissue. 



































Table S1:  Patient Cohort Details  ( n=1126 )____ 
 
Age at diagnosisa__________________________________ 
 median (min - max)   61 (20-98) 
 
Tumor diameter (cm) b______________________________ 
 median (min - max)    2.2 (0.1-15) 
 
Follow-up time (months)c____________________________ 
 mean (min - max)    8.5 (1 - 168) 
 median     52 
 
Tumor graded_____________________________________ 
 G1     177 (15.9%)    
 G2     524 (46.9%) 
 G3     415 (37.2%) 
 
Tumor stagee   ________________________ 
 pT1     465 (41.5%)  
 pT2     489 (43.6%) 
 pT3       50 (  4.5%) 
 pT4     117 (10.4%) 
 
Axillary nodal statusf_______________________________ 
 Node negative (pN0)    265 (32.8%) 
 Node positive (pN1-3)   543 (67.2%) 
 
ER statusg_______________________________________ 
 Negative    212 (19.8%) 
 Positive    857 (80.2%) 
 
E-cadherin statush_________________________________ 
 Negative    60 (  5.6%) 
 Positive           1021 (94.4%) 
 
HER2 statusi_____________________________________ 
 HER2 not amplified    925 (85.6%)   
 HER2 amplified    155 (14.4%) 
 
Survivalj_________________________________________ 
 5 year       77.3 % 
          10 year       60.0 % 
_______________________________________________ 
a 174 cases missing       f 318 cases missing    
b    5 cases missing       g   57 cases missing   
c 191 cases missing       h  45 cases missing    
d  10 cases missing       i  46 cases missingi       
e    5 cases missing        j  % given as valid % 
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